Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder.

The Libyan Journal of Medicine Pub Date : 2012-01-01 Epub Date: 2012-03-08 DOI:10.3402/ljm.v7i0.14694
Khaled El Gehani, Lamia Al-Kikhia, Fatma Emaetig, Kari Syrjänen, Omran Al-Fituri, Adam Elzagheid
{"title":"Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder.","authors":"Khaled El Gehani,&nbsp;Lamia Al-Kikhia,&nbsp;Fatma Emaetig,&nbsp;Kari Syrjänen,&nbsp;Omran Al-Fituri,&nbsp;Adam Elzagheid","doi":"10.3402/ljm.v7i0.14694","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The frequency of over-expression of human epidermal growth factor receptor-2 (HER-2) in bladder cancer is one of the highest among all human malignancies. This over-expression is thought to play a role in aberrant proliferation of cancer cells. Studies on HER-2 expression in bladder carcinoma have shown heterogeneous results.</p><p><strong>Purpose: </strong>The aim of the study was to evaluate the status of HER-2 protein expression in patients with invasive carcinomas of the urinary bladder as related to tumor grade and stage.</p><p><strong>Materials and methods: </strong>Archival samples from 39 patients (6 women, 33 males) with urinary bladder cancer were analyzed for HER-2 over-expression, using immunohistochemistry with the HercepTest.</p><p><strong>Results: </strong>HER-2 over-expression was observed in 23/39 tumors (59%) and was more frequent in high-grade than in low-grade carcinomas, but the difference was not statistically significant. A significant correlation was established between HER-2 over-expression and tumor stage (p=0.011). HER-2 expression was more frequent in transitional cell carcinomas (TCC) and adenocarcinomas (AC) as compared with squamous cell carcinoma (SCC). Patients' age and sex were not related to HER-2 over-expression.</p><p><strong>Conclusion: </strong>Over-expression of HER-2 was frequent in carcinomas of the urinary bladder. Knowing the HER-2 status would be helpful in formulating a rational treatment strategy for patients with urinary bladder cancer.</p>","PeriodicalId":256060,"journal":{"name":"The Libyan Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3402/ljm.v7i0.14694","citationCount":"18","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Libyan Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3402/ljm.v7i0.14694","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/3/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 18

Abstract

Background: The frequency of over-expression of human epidermal growth factor receptor-2 (HER-2) in bladder cancer is one of the highest among all human malignancies. This over-expression is thought to play a role in aberrant proliferation of cancer cells. Studies on HER-2 expression in bladder carcinoma have shown heterogeneous results.

Purpose: The aim of the study was to evaluate the status of HER-2 protein expression in patients with invasive carcinomas of the urinary bladder as related to tumor grade and stage.

Materials and methods: Archival samples from 39 patients (6 women, 33 males) with urinary bladder cancer were analyzed for HER-2 over-expression, using immunohistochemistry with the HercepTest.

Results: HER-2 over-expression was observed in 23/39 tumors (59%) and was more frequent in high-grade than in low-grade carcinomas, but the difference was not statistically significant. A significant correlation was established between HER-2 over-expression and tumor stage (p=0.011). HER-2 expression was more frequent in transitional cell carcinomas (TCC) and adenocarcinomas (AC) as compared with squamous cell carcinoma (SCC). Patients' age and sex were not related to HER-2 over-expression.

Conclusion: Over-expression of HER-2 was frequent in carcinomas of the urinary bladder. Knowing the HER-2 status would be helpful in formulating a rational treatment strategy for patients with urinary bladder cancer.

Abstract Image

Abstract Image

HER-2的过表达与膀胱癌的分期有关。
背景:人表皮生长因子受体-2 (HER-2)在膀胱癌中的过表达频率是所有人类恶性肿瘤中最高的之一。这种过度表达被认为在癌细胞的异常增殖中起作用。对膀胱癌中HER-2表达的研究显示出不同的结果。目的:研究浸润性膀胱癌患者HER-2蛋白表达与肿瘤分级和分期的关系。材料与方法:对39例膀胱癌患者(女性6例,男性33例)的档案样本进行HER-2过表达分析,采用免疫组织化学方法结合HercepTest。结果:39例肿瘤中有23例(59%)存在HER-2过表达,高级别肿瘤中HER-2过表达高于低级别肿瘤,但差异无统计学意义。HER-2过表达与肿瘤分期有显著相关性(p=0.011)。HER-2在移行细胞癌(TCC)和腺癌(AC)中的表达较鳞状细胞癌(SCC)更为频繁。患者的年龄和性别与HER-2过表达无关。结论:HER-2在膀胱癌中高表达较为常见。了解HER-2水平有助于制定合理的膀胱癌治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信